176 related articles for article (PubMed ID: 31440380)
1. Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension.
Li T; Zha L; Luo H; Li S; Zhao L; He J; Li X; Qi Q; Liu Y; Yu Z
Aging Dis; 2019 Aug; 10(4):731-745. PubMed ID: 31440380
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension.
Luo H; Liu B; Zhao L; He J; Li T; Zha L; Li X; Qi Q; Liu Y; Yu Z
J Am Soc Hypertens; 2017 Oct; 11(10):673-683.e3. PubMed ID: 28826890
[TBL] [Abstract][Full Text] [Related]
3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.
Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y
Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608
[TBL] [Abstract][Full Text] [Related]
4. Endothelial-to-mesenchymal transition in pulmonary hypertension.
Ranchoux B; Antigny F; Rucker-Martin C; Hautefort A; Péchoux C; Bogaard HJ; Dorfmüller P; Remy S; Lecerf F; Planté S; Chat S; Fadel E; Houssaini A; Anegon I; Adnot S; Simonneau G; Humbert M; Cohen-Kaminsky S; Perros F
Circulation; 2015 Mar; 131(11):1006-18. PubMed ID: 25593290
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4.
He J; Li X; Luo H; Li T; Zhao L; Qi Q; Liu Y; Yu Z
J Am Soc Hypertens; 2017 May; 11(5):275-289.e2. PubMed ID: 28431936
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 aggravates pulmonary arterial hypertension via immunomodulation in congenital heart disease.
Shen Q; Chen W; Liu J; Liang Q
Life Sci; 2019 Sep; 232():116546. PubMed ID: 31176777
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3- Mediated Transdifferentiation of Pulmonary Artery Endothelial Cells Contributes to Hypoxic Pulmonary Vascular Remodeling.
Zhang L; Li YM; Zeng XX; Wang XY; Chen SK; Gui LX; Lin MJ
Cell Physiol Biochem; 2018; 51(2):763-777. PubMed ID: 30463073
[TBL] [Abstract][Full Text] [Related]
8. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Zhao H; Wang Y; Zhang X; Guo Y; Wang X
Toxicol Appl Pharmacol; 2020 Jan; 386():114827. PubMed ID: 31734320
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.
de Mendonça L; Felix NS; Blanco NG; Da Silva JS; Ferreira TP; Abreu SC; Cruz FF; Rocha N; Silva PM; Martins V; Capelozzi VL; Zapata-Sudo G; Rocco PRM; Silva PL
Stem Cell Res Ther; 2017 Oct; 8(1):220. PubMed ID: 28974252
[TBL] [Abstract][Full Text] [Related]
10. Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.
Good RB; Gilbane AJ; Trinder SL; Denton CP; Coghlan G; Abraham DJ; Holmes AM
Am J Pathol; 2015 Jul; 185(7):1850-8. PubMed ID: 25956031
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
12. The role of PDGF-B/TGF-β1/neprilysin network in regulating endothelial-to-mesenchymal transition in pulmonary artery remodeling.
Song S; Zhang M; Yi Z; Zhang H; Shen T; Yu X; Zhang C; Zheng X; Yu L; Ma C; Liu Y; Zhu D
Cell Signal; 2016 Oct; 28(10):1489-501. PubMed ID: 27373199
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
14. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
15. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.
Liu HM; Jia Y; Zhang YX; Yan J; Liao N; Li XH; Tang Y
Acta Pharmacol Sin; 2019 Apr; 40(4):477-485. PubMed ID: 30038339
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension.
Zhao H; Xue Y; Guo Y; Sun Y; Liu D; Wang X
Int Immunopharmacol; 2017 Jan; 42():115-121. PubMed ID: 27912147
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.
Fulton DJR; Li X; Bordan Z; Wang Y; Mahboubi K; Rudic RD; Haigh S; Chen F; Barman SA
Antioxid Redox Signal; 2019 Nov; 31(14):1053-1069. PubMed ID: 30767565
[No Abstract] [Full Text] [Related]
20. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
